Literature DB >> 116543

Evaluation of the moving intermediate zone concept for determing susceptibility of pseudomonads to gentamicin by the standardized disk agar-diffusion test.

B F Woolfrey, W A Ramadei, C O Quall.   

Abstract

The usefulness of the moving intermediate zone concept for improving the performance of the standardized disk agar-diffusion test in measuring susceptibility of the fluorescent group of pseudomonads to gentamicin was studied. For this purpose, a 3-mm moving intermediate zone lying --3 mm and --6 mm below that measured for the quality control microorganism Pseudomonas aeruginosa, ATCC 27853, and a wider moving intermediate zone lying --2 mm and --7 mm below that for the quality control microorganism were investigated. Data from the authors' previous study of the usefulness of using fixed breakpoints and fixed zones for assessing susceptibility of the fluorescent pseudomonads to gentamicin were used for this analysis. The results indicate that both the 3-mm moving intermediate zone and the wider 5-mm moving intermediate zone produced unacceptably high rates of error for testing the susceptibility of the fluorescent group of pseudomonads to gentamicin by the standardized disk agar-diffusion test.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 116543     DOI: 10.1093/ajcp/72.5.861

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  Error rates associated with the use of recently proposed breakpoints for testing Pseudomonas aeruginosa versus gentamicin, tobramycin, and amikacin by the standardized disk agar diffusion test.

Authors:  B F Woolfrey; J M Fox; C O Quall; R T Lally
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

2.  Broth microdilution testing of Pseudomonas aeruginosa and aminoglycosides: need for employing dilutions differing by small arithmetic increments.

Authors:  B F Woolfrey; J M Fox; R T Lally; C O Quall
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.